ProKidney Corp
PROK2.710USD
+0.180+7.11%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
361.57MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über ProKidney Corp Unternehmen
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Unternehmensinformationen
BörsenkürzelPROK
Name des UnternehmensProKidney Corp
IPO-datumJun 30, 2021
CEODr. Bruce Culleton, M.D.
Anzahl der mitarbeiter204
WertpapierartOrdinary Share
GeschäftsjahresendeJun 30
Addresse2000 Frontis Plaza Blvd.
StadtWINSTON-SALEM
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl27103
Telefon13369997028
Websitehttps://prokidney.com/
BörsenkürzelPROK
IPO-datumJun 30, 2021
CEODr. Bruce Culleton, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Lucio Tozzi
Mr. Lucio Tozzi
Senior Vice President - Global Clinical Operations
Senior Vice President - Global Clinical Operations
--
--
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Sep 2
Aktualisiert: Tue, Sep 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Tolerantia LLC
16.75%
Suvretta Capital Management, LLC
9.14%
Control Empresarial de Capitales, S.A. de C.V.
7.94%
Morgan Stanley Investment Management Inc. (US)
4.23%
BlackRock Mexico Operadora SA de CV SOFI
2.54%
Andere
59.39%
Aktionäre
Aktionäre
Anteil
Tolerantia LLC
16.75%
Suvretta Capital Management, LLC
9.14%
Control Empresarial de Capitales, S.A. de C.V.
7.94%
Morgan Stanley Investment Management Inc. (US)
4.23%
BlackRock Mexico Operadora SA de CV SOFI
2.54%
Andere
59.39%
Aktionärstypen
Aktionäre
Anteil
Corporation
24.70%
Investment Advisor
10.51%
Hedge Fund
10.27%
Investment Advisor/Hedge Fund
5.98%
Research Firm
2.88%
Individual Investor
1.92%
Endowment Fund
0.74%
Family Office
0.04%
Bank and Trust
0.04%
Andere
42.93%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
187
92.52M
71.43%
-12.19M
2025Q1
188
90.99M
70.46%
-13.35M
2024Q4
184
92.39M
74.12%
+21.48M
2024Q3
176
90.75M
73.53%
+26.28M
2024Q2
216
81.85M
70.67%
+19.77M
2024Q1
231
37.73M
58.52%
-31.32M
2023Q4
239
39.92M
63.74%
-31.95M
2023Q3
236
64.28M
104.12%
-21.16M
2023Q2
223
59.02M
95.83%
-21.49M
2023Q1
183
53.54M
87.01%
-23.74M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Tolerantia LLC
22.62M
17.46%
--
--
Jun 03, 2025
Suvretta Capital Management, LLC
12.34M
9.53%
--
--
Mar 31, 2025
Control Empresarial de Capitales, S.A. de C.V.
10.72M
8.28%
+2.28M
+27.04%
Apr 22, 2025
Morgan Stanley Investment Management Inc. (US)
10.04M
7.75%
-3.51M
-25.90%
Mar 31, 2025
BlackRock Mexico Operadora SA de CV SOFI
3.43M
2.65%
--
--
Mar 31, 2025
Operadora de Fondos GBM S.A.B. de C.V.
2.45M
1.89%
--
--
May 31, 2025
Bleichroeder LP
2.00M
1.54%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.32M
4.88%
+8.24K
+0.13%
Mar 31, 2025
The Vanguard Group, Inc.
5.21M
4.02%
-63.88K
-1.21%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
